BioThrax approvded by the Singapore Health Sciences Authority

Emergent BioSolutions, Inc., recently announced that the Singapore Health Sciences Authority has approved its product licensing agreement for BioThrax, a vaccine to fight anthrax infection.

The Singapore HAS is the statutory board of the Singapore Ministry of Health. It administers the regulatory framework for pharmaceuticals, medical devices and health products in general.

"Emergent is pleased with this development as it continues to grow its presence in the Pacific Rim," Daniel J. Abdun-Nabi, president and chief operating officer of Emergent BioSolutions, Inc., said. "With HSA approval of BioThrax, we look forward to initiating discussions with the government of Singapore, as well as other allied governments that recognize HSA registered products such as Brunei, to help protect their constituents against the threat of anthrax as a biological weapon."

BioThrax is the only anthrax vaccine approved by the U.S. Food and Drug Administration. It is indicated for the immunization of adults with a high risk of exposure to anthrax. The vaccine is manufactured from a non-virulent strain of the bacteria Bacillus anthracis.

Emergent BioSolutions, Inc., has already delivered 42 million doses of the vaccine to the U.S. government and continues to do so under existing procurement contracts. Since 1998, 2.5 million military personnel have received 10 million doses of the vaccine.